3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Polycythemia Vera
2
Myeloproliferative Disorders
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Thymic aplasia
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Severe Combined Immunodeficiency
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Dysautonomias
1
Polycystic Ovary Syndrome
1
Neuroblastoma
1
Neoplasms
1
Mucopolysaccharidosis I
1
Metabolic Syndrome
1
Melanoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Insulin Resistance
1
Immunologic Deficiency Syndromes
1
Hyperandrogenism
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Interventions
aldesleukin
26
Sunitinib
25
Interferon-alpha
21
Everolimus
18
Sorafenib
16
Cyclophosphamide
16
Filgrastim
13
Bevacizumab
13
Nivolumab
11
Gemcitabine
11
Interleukin-2
10
Axitinib
10
fludarabine phosphate
9
Gene Expression Profiling
9
temsirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Doxorubicin
8
pembrolizumab
7
Radiotherapy
6
Radiosurgery
6
Polymerase Chain Reaction
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Ifosfamide
5
Fluorouracil
5
Erlotinib Hydrochloride
5
Capecitabine
5
Bortezomib
5
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Kidney Neoplasms
×
Phlebotomy
×
Clear all
NCT04154163
2022-02-28
ADOPT
University of Dundee
Completed
18 enrolled